10-Q: Atossa Therapeutics Reports Q1 2025 Financial Results, Highlights Ongoing Clinical Trials

Atossa Therapeutics reports a net loss of $6.7 million for Q1 2025 while advancing its (Z)-endoxifen clinical programs.

Summary

• Atossa Therapeutics reported a net loss of $6.7 million for the three months ended March 31, 2025, compared to a net loss of $5.9 million for the same period in 2024.
• The company's cash and cash equivalents totaled $65.1 million as of March 31, 2025, with working capital of $63.3 million.
• Atossa believes its current cash is sufficient to fund operations for at least the next 12 months.
• Research and development expenses increased to $4.2 million from $3.7 million year-over-year, driven by compensation and professional fees.
• General and administrative expenses remained relatively stable at $3.3 million.
• The company is focused on developing (Z)-endoxifen for breast cancer prevention and treatment, including metastatic breast cancer, DCIS, and neoadjuvant therapy.
• Clinical trials are ongoing for (Z)-endoxifen in various settings, including the EVANGELINE study and the I-SPY 2 EOP trial.
• Atossa is facing patent challenges from Intas Pharmaceuticals regarding its endoxifen patents and intends to vigorously contest them.
• The company is working to regain compliance with Nasdaq's minimum bid price requirement.
• Atossa has an at-the-market offering facility with Jefferies LLC to sell shares of common stock up to an aggregate offering price of $100.0 million, but no sales were made during the quarter.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is making progress in its clinical trials, it is also facing financial challenges and patent disputes. The company's ability to regain compliance with Nasdaq listing requirements is also a concern.

Positives

• Atossa has $65.1 million in cash and cash equivalents, which is expected to fund operations for at least the next 12 months.
• Clinical trials are progressing for (Z)-endoxifen in various breast cancer settings.
• The company is actively pursuing a metastatic breast cancer indication for (Z)-endoxifen, which may offer a streamlined regulatory pathway.
• The Treatment Cohort in the EVANGELINE study was initiated in April 2025.
• Preliminary data from the I-SPY 2 EOP trial showed (Z)-endoxifen met the primary endpoint with 95% (19/20 patients) receiving > 75 % of planned treatment.
• The data also showed (Z)-endoxifen activity in rapidly reducing key biomarkers, such as Ki-67, by 69% from baseline and a 30.4% reduction in functional tumor volume (FTV) from baseline after three weeks of treatment.
• The 1 mg dose of (Z)-endoxifen reduced MBD by 17.3% (p<0.01), while the 2 mg dose achieved a reduction of 23.5% (p<0.01), compared to a minimal change in the placebo group of 0.27%.

Negatives

• Atossa reported a net loss of $6.7 million for Q1 2025 and has a history of operating losses.
• The company is facing patent challenges from Intas Pharmaceuticals regarding its endoxifen patents.
• Atossa is not in compliance with Nasdaq's minimum bid price requirement and must regain compliance by August 20, 2025.
• Interest income decreased by $0.4 million due to a decrease in the balance in the money market account.
• Based on input from the FDA and Swedish Medical Products Agency, reduction in MBD may not be an approvable indication unless we can demonstrate that our (Z)-endoxifen also reduces the incidence of breast cancer.

Risks

• The company's ability to continue as a going concern depends on obtaining adequate capital.
• Clinical trials may not demonstrate the efficacy and safety of product candidates.
• The company is dependent on third-party service providers for critical operational activities.
• The company is facing patent challenges from Intas Pharmaceuticals.
• The company is not in compliance with Nasdaq's minimum bid price requirement.
• Legislative or regulatory reforms may make it more difficult and costly to obtain regulatory approval.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company's ability to use net operating loss carryforwards and research tax credits to reduce future tax payments may be limited or restricted.

Future Outlook

Atossa plans to continue funding its operations through a combination of public or private equity offerings, debt financings, or other sources, including potential corporate collaborations, licenses, and other similar arrangements. The company believes it has sufficient cash on hand to fund its projected operating requirements for at least the next 12 months.

Management Comments

• Management believes its currently available cash and cash equivalents will be sufficient to finance the Company's operations for at least one year from the date these Condensed Consolidated Financial Statements are issued.

Industry Context

Atossa is operating in the competitive biopharmaceutical industry, focusing on breast cancer therapeutics. The company's (Z)-endoxifen program targets significant unmet medical needs in oncology, particularly in breast cancer prevention and treatment. The development of novel therapies for breast cancer is a major area of focus for many pharmaceutical and biotechnology companies, reflecting the high prevalence and unmet needs in this disease area.

Comparison to Industry Standards

• It is difficult to compare Atossa's results directly to industry standards without knowing the specific stage and focus of comparable companies.
• However, early-stage biotech companies often report net losses as they invest heavily in research and development.
• A company like Clovis Oncology, before its acquisition, focused on oncology and faced similar challenges in funding and clinical development.
• Similarly, companies like Puma Biotechnology, which commercialized Nerlynx for HER2-positive breast cancer, provide a benchmark for the potential commercial success of targeted breast cancer therapies.
• Atossa's cash position of $65.1 million is relatively strong for a company of its size and stage, providing a runway for continued clinical development.
• However, the company will need to raise additional capital in the future to fund its operations and achieve its long-term goals.

Legal Proceedings

• Intas Pharmaceuticals Ltd. filed a Petition for Post Grant Review (PGR) with the U.S. Patent and Trademark Offices (USPTO) Patent Trial and Appeal Board (PTAB) (the 391 PGR Petition) seeking to invalidate one of the Company's issued patents (U.S. Patent No. 12,071,391) titled Methods for Making and Using Endoxifen, on the alleged grounds of anticipation, obviousness, lack of written description, and lack of enablement.
• Intas also filed a Petition for Inter Partes Review (IPR) with the USPTOs PTAB (the 151 IPR Petition) seeking to invalidate one of the Company's issued patents (U.S. Patent No. 11,261,151) titled Methods for Making and Using Endoxifen (together with U.S. Patent No. 12,071,391, the Patents) on the alleged grounds of anticipation and obviousness.
• The Company intends to vigorously contest the 391 PGR Petition and the 151 IPR Petition and believes that the Patents were properly granted and include valid and enforceable claims.

Stakeholder Impact

• Shareholders: The company's financial performance and stock price are key concerns for shareholders.
• Employees: The company's ability to secure funding and advance its clinical programs impacts job security and opportunities for growth.
• Patients: The success of (Z)-endoxifen clinical trials could provide new treatment options for breast cancer patients.
• Creditors: The company's financial stability and ability to repay debts are important considerations for creditors.
• Suppliers: The company's ongoing operations and clinical trials provide business opportunities for suppliers of materials and services.

Next Steps

• Continue clinical trials for (Z)-endoxifen in various breast cancer settings.
• Pursue a metastatic breast cancer indication for (Z)-endoxifen.
• Contest patent challenges from Intas Pharmaceuticals.
• Regain compliance with Nasdaq's minimum bid price requirement.
• Explore potential corporate collaborations, licenses, and other similar arrangements.

Key Dates

Keywords

Atossa Therapeutics, Z-endoxifen, Breast Cancer, Clinical Trials, Financial Results, Metastatic Breast Cancer, Ductal Carcinoma In Situ, Neoadjuvant Treatment, Mammographic Breast Density, Nasdaq Compliance